Cargando…
SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
Diabetes is a complex disease of increasingly common occurrence worldwide. Attaining optimal glycemic control is the main challenge to prevent the development of diabetes-related complications and/or to stop their progression. In recent years, the pharmacologic toolkit for the treatment of diabetes...
Autores principales: | Spatola, Leonardo, Finazzi, Silvia, Angelini, Claudio, Dauriz, Marco, Badalamenti, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801228/ https://www.ncbi.nlm.nih.gov/pubmed/29177922 http://dx.doi.org/10.1007/s13300-017-0342-8 |
Ejemplares similares
-
Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019) -
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021) -
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021) -
Class effect for SGLT-2 inhibitors: a tale of 9 drugs
por: Giugliano, Dario, et al.
Publicado: (2019) -
Structural mechanism of SGLT1 inhibitors
por: Niu, Yange, et al.
Publicado: (2022)